Patents by Inventor Bhaskara Rao Nallaganchu

Bhaskara Rao Nallaganchu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo [1,2-a]pyrido[3,4-e]pyrimidin-5(1H)-one, analogs thereof, and salts thereof and methods for their use in therapy
    Patent number: 11976068
    Abstract: This disclosure relates to methods of treatment using compound (1) or analogs thereof, and pharmaceutically acceptable salts thereof. Also disclosed are compounds of formula (10): as defined in the specification, and pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions comprising the same. Methods of treatment, such as for cancer, are provided that comprise administering the compounds and their salts to a subject in need of such treatment.
    Type: Grant
    Filed: June 24, 2021
    Date of Patent: May 7, 2024
    Assignee: ONCOCEUTICS, INC.
    Inventors: Joshua E. Allen, Martin Stogniew, Richard S. Pottorf, Bhaskara Rao Nallaganchu, Gary Olson, Yanjun Sun
  • Process of making derivatives of substituted morpholines
    Patent number: 11964951
    Abstract: Provided here are methods of making derivatives and prodrugs of substituted morpholines or pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: June 7, 2023
    Date of Patent: April 23, 2024
    Assignee: Supernus Pharmaceuticals, Inc.
    Inventors: Yanjun Sun, Bhaskara Rao Nallaganchu, Gary L. Olson
  • PROCESS OF MAKING DERIVATIVES OF SUBSTITUTED MORPHOLINES
    Publication number: 20230357173
    Abstract: Provided here are methods of making derivatives and prodrugs of substituted morpholines or pharmaceutically acceptable salts thereof.
    Type: Application
    Filed: June 7, 2023
    Publication date: November 9, 2023
    Applicant: Supernus Pharmaceuticals, Inc.
    Inventors: Yanjun Sun, Bhaskara Rao Nallaganchu, Gary L. Olson
  • PROCESS OF MAKING DERIVATIVES OF SUBSTITUTED MORPHOLINES
    Publication number: 20230295100
    Abstract: Provided here are methods of making derivatives and prodrugs of substituted morpholines or pharmaceutically acceptable salts thereof.
    Type: Application
    Filed: March 17, 2023
    Publication date: September 21, 2023
    Applicant: Supernus Pharmaceuticals, Inc.
    Inventors: Yanjun Sun, Bhaskara Rao Nallaganchu, Gary L. Olson
  • 7-BENZYL-4-(2-METHYLBENZYL)-2,4,6,7,8,9-HEXAHYDROIMIDAZO [1,2-a]PYRIDO[3,4-e]PYRIMIDIN-5(1H)-ONE, ANALOGS THEREOF, AND SALTS THEREOF AND METHODS FOR THEIR USE IN THERAPY
    Publication number: 20220017519
    Abstract: This disclosure relates to methods of treatment using compound (1) or analogs thereof, and pharmaceutically acceptable salts thereof. Also disclosed are compounds of formula (10): as defined in the specification, and pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions comprising the same. Methods of treatment, such as for cancer, are provided that comprise administering the compounds and their salts to a subject in need of such treatment.
    Type: Application
    Filed: June 24, 2021
    Publication date: January 20, 2022
    Inventors: Joshua E. ALLEN, Martin STOGNIEW, Richard S. POTTORF, Bhaskara Rao NALLAGANCHU, Gary OLSON, Yanjun SUN
  • 7-BENZYL-4-(2-METHYLBENZYL)-2,4,6,7,8,9-HEXAHYDROIMIDAZO [1,2-A]PYRIDO[3,4-E]PYRIMIDIN-5(1H)-ONE, ANALOGS THEREOF, AND SALTS THEREOF AND METHODS FOR THEIR USE IN THERAPY
    Publication number: 20190194201
    Abstract: This disclosure relates to methods of treatment using compound (1) or analogs thereof, and pharmaceutically acceptable salts thereof. Also disclosed are compounds of formula (10): as defined in the specification, and pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions comprising the same. Methods of treatment, such as for cancer, are provided that comprise administering the compounds and their salts to a subject in need of such treatment.
    Type: Application
    Filed: February 27, 2019
    Publication date: June 27, 2019
    Applicant: ONCOCEUTICS, INC.
    Inventors: Joshua E. ALLEN, Martin STOGNIEW, Richard S. POTTORF, Bhaskara Rao NALLAGANCHU, Gary OLSON, Yanjun SUN
  • 7-Benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo [1,2-A]pyrido[3,4-E]pyrimidin-5(1H)-one, analogs thereof, and salts thereof and methods for their use in therapy
    Patent number: 10266533
    Abstract: This disclosure relates to methods of treatment using compound (1) or analogs thereof, and pharmaceutically acceptable salts thereof. Also disclosed are compounds of formula (10): as defined in the specification, and pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions comprising the same. Methods of treatment, such as for cancer, are provided that comprise administering the compounds and their salts to a subject in need of such treatment.
    Type: Grant
    Filed: November 20, 2017
    Date of Patent: April 23, 2019
    Assignee: Oncoceutics, Inc.
    Inventors: Joshua E. Allen, Martin Stogniew, Richard S. Pottorf, Bhaskara Rao Nallaganchu, Gary Olson, Yanjun Sun
  • 7-BENZYL-4-(2-METHYLBENZYL)-2,4,6,7,8,9-HEXAHYDROIMIDAZO [1,2-A]PYRIDO[3,4-E]PYRIMIDIN-5(1H)-ONE, ANALOGS THEREOF, AND SALTS THEREOF AND METHODS FOR THEIR USE IN THERAPY
    Publication number: 20180072729
    Abstract: This disclosure relates to methods of treatment using compound (1) or analogs thereof, and pharmaceutically acceptable salts thereof. Also disclosed are compounds of formula (10): as defined in the specification, and pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions comprising the same. Methods of treatment, such as for cancer, are provided that comprise administering the compounds and their salts to a subject in need of such treatment.
    Type: Application
    Filed: November 20, 2017
    Publication date: March 15, 2018
    Applicant: ONCOCEUTICS, INC.
    Inventors: Joshua E. ALLEN, Martin STOGNIEW, Richard S. POTTORF, Bhaskara Rao NALLAGANCHU, Gary OLSON, Yanjun SUN
  • 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo [1,2-A]pyrido[3,4-E]pyrimidin-5(1H)-one, analogs thereof, and salts thereof and methods for their use in therapy
    Patent number: 9845324
    Abstract: This disclosure relates to methods of treatment using compound (1) or analogs thereof, and pharmaceutically acceptable salts thereof. Also disclosed are compounds of formula (10): as defined in the specification, and pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions comprising the same. Methods of treatment, such as for cancer, are provided that comprise administering the compounds and their salts to a subject in need of such treatment.
    Type: Grant
    Filed: February 22, 2016
    Date of Patent: December 19, 2017
    Assignee: Oncoceutics, Inc.
    Inventors: Joshua E. Allen, Martin Stogniew, Richard S. Pottorf, Bhaskara Rao Nallaganchu, Gary Olson, Yanjun Sun
  • 7-BENZYL-4-(2-METHYLBENZYL)-2,4,6,7,8,9-HEXAHYDROIMIDAZO [1,2-A]PYRIDO[3,4-E]PYRIMIDIN-5(1H)-ONE, ANALOGS THEREOF, AND SALTS THEREOF AND METHODS FOR THEIR USE IN THERAPY
    Publication number: 20170096431
    Abstract: This disclosure relates to methods of treatment using compound (1) or analogs thereof, and pharmaceutically acceptable salts thereof. Also disclosed are compounds of formula (10): as defined in the specification, and pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions comprising the same. Methods of treatment, such as for cancer, are provided that comprise administering the compounds and their salts to a subject in need of such treatment.
    Type: Application
    Filed: February 22, 2016
    Publication date: April 6, 2017
    Applicants: ONCOCEUTICS INC., PROVID PHARMACEUTICALS INC.
    Inventors: Joshua E. Allen, Martin Stogniew, Richard S. Pottorf, Bhaskara Rao Nallaganchu, Gary Olson, Yanjun Sun
  • Arginase inhibitors and methods of use thereof
    Patent number: 9447122
    Abstract: The present invention includes arginase enzyme inhibitors, compositions comprising these arginase inhibitors, and methods of treating or diagnosing conditions characterized either by abnormally high arginase activity or abnormally low nitric oxide levels in a mammal, comprising administering compositions of the invention to the mammal.
    Type: Grant
    Filed: March 19, 2015
    Date of Patent: September 20, 2016
    Assignee: AstraZeneca AB
    Inventors: Bruce Edward Tomczuk, Gary Lee Olson, Richard Scott Pottorf, Lijuan Jane Wang, Bhaskara Rao Nallaganchu, Yanqun Zhang
  • 7-BENZYL-4-(METHYLBENZYL)-2,4,6,7,8,9-HEXAHYDROIMIDAZO[1,2-A]PYRIDO[3,4-E]PYRIMIDIN-5 (1H)-ONE, SALTS THEREOF AND METHODS OF USING THE SAME IN COMBINATION THERAPY
    Publication number: 20160264574
    Abstract: This disclosure relates, at least in part, to a method of treatment. In one embodiment, the method of treatment comprises administering to a subject in need of such treatment a first therapeutic agent including compound (1): (structurally represented) or a pharmaceutically acceptable salt thereof in combination with a second therapeutic agent, wherein the first therapeutic agent and the second therapeutic agent are administered either simultaneously or sequentially.
    Type: Application
    Filed: September 12, 2014
    Publication date: September 15, 2016
    Applicants: ONCOCEUTICS, INC., PROV PHARMACEUTICALS INC.
    Inventors: Martin STOGNIEW, Joshua E ALLEN, Richard S. POTTORF, Bhaskara Rao NALLAGANCHU, Gary OLSON
  • 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1H)-one, salts thereof and methods of using the same in combination therapy
    Patent number: 9376437
    Abstract: This disclosure relates, at least in part, to a method of treatment. In one embodiment, the method of treatment comprises administering to a subject in need of such treatment a first therapeutic agent including compound (1): or a pharmaceutically acceptable salt thereof in combination with a second therapeutic agent, wherein the first therapeutic agent and the second therapeutic agent are administered either simultaneously or sequentially.
    Type: Grant
    Filed: July 25, 2014
    Date of Patent: June 28, 2016
    Assignee: Oncoceutics, Inc
    Inventors: Martin Stogniew, Joshua E. Allen, Richard S. Pottorf, Bhaskara Rao Nallaganchu, Gary Olson
  • 7-benzyl-10-(2-methylbenzyl)-2,6,7,8,9,10-hexahydroimidazo[1,2-A]pyrido[4,3-D]pyrimidin-5(3H)-one, salts thereof and methods of using the same in combination therapy
    Patent number: 9265765
    Abstract: This disclosure relates, at least in part, to a method of treatment. In one embodiment, the method of treatment comprises administering to a subject in need of such treatment a first therapeutic agent including compound (1): or a pharmaceutically acceptable salt thereof in combination with a second therapeutic agent, wherein the first therapeutic agent and the second therapeutic agent are administered either simultaneously or sequentially.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: February 23, 2016
    Assignee: Oncoceutics, Inc.
    Inventors: Martin Stogniew, Joshua E. Allen, Richard S. Pottorf, Bhaskara Rao Nallaganchu, Gary Olson
  • Arginase Inhibitors and Methods of Use Thereof
    Publication number: 20160039847
    Abstract: The present invention includes arginase enzyme inhibitors, compositions comprising these arginase inhibitors, and methods of treating or diagnosing conditions characterized either by abnormally high arginase activity or abnormally low nitric oxide levels in a mammal, comprising administering compositions of the invention to the mammal.
    Type: Application
    Filed: March 19, 2015
    Publication date: February 11, 2016
    Inventors: Bruce Edward Tomczuk, Gary Lee Olson, Richard Scott Pottorf, Lijuan Jane Wang, Bhaskara Rao Nallaganchu, Yanqun Zhang
  • Arginase inhibitors and methods of use thereof
    Patent number: 8894970
    Abstract: The present invention includes arginase enzyme inhibitors, compositions comprising these arginase inhibitors, and methods of treating or diagnosing conditions characterized either by abnormally high arginase activity or abnormally low nitric oxide levels in a mammal, comprising administering compositions of the invention to the mammal.
    Type: Grant
    Filed: July 26, 2011
    Date of Patent: November 25, 2014
    Assignee: Corridor Pharmaceuticals, Inc.
    Inventors: Bruce Edward Tomczuk, Gary Lee Olson, Richard Scott Pottorf, Lijuan Jane Wang, Bhaskara Rao Nallaganchu, Yanqun Zhang
  • Arginase Inhibitors and Methods of Use Thereof
    Publication number: 20120171116
    Abstract: The present invention includes arginase enzyme inhibitors, compositions comprising these arginase inhibitors, and methods of treating or diagnosing conditions characterized either by abnormally high arginase activity or abnormally low nitric oxide levels in a mammal, comprising administering compositions of the invention to the mammal.
    Type: Application
    Filed: July 26, 2011
    Publication date: July 5, 2012
    Inventors: Bruce Edward Tomczuk, Gary Lee Olson, Richard Scott Pottorf, Jane Wang, Bhaskara Rao Nallaganchu